| Literature DB >> 35264358 |
David Sibbritt1, Tobias Sundberg2, Lesley Ward1, Alex Broom3, Jane Frawley1, Jessica Bayes4, Jon Adams1.
Abstract
OBJECTIVE: To examine the use and out-of-pocket expenses resulting from consultations, products and practices across conventional, self-care, and complementary medicine (CM) treatments for osteoarthritis (OA) among Australian women. DESIGN, SETTING AND PARTICIPANTS: A cross-sectional survey of 800 women from the 45 and Up Study who had reported a clinical diagnosis of OA. OUTCOME MEASURES: Women's use of conventional, CM and self-prescribed treatments for OA and the associated out-of-pocket cost.Entities:
Keywords: musculoskeletal disorders; pain management; rheumatology
Mesh:
Year: 2022 PMID: 35264358 PMCID: PMC8915347 DOI: 10.1136/bmjopen-2021-055468
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Consultations with healthcare practitioners by years since diagnosis of osteoarthritis and severity of osteoarthritis over the past 12 months
| Osteoarthritis characteristics | Average number of consultations | |||||
| Doctor | Allied health | CM | Total | |||
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |||
| Years since diagnosis | <10 years | (n=120) | 2.1 (2.4) | 1.1 (2.4) | 2.6 (5.2) | 5.8 (7.2) |
| ≥10 years | (n=253) | 3.5 (3.8) | 2.8 (4.4) | 2.7 (4.9) | 8.9 (9.7) | |
| P value | <0.001* | <0.001* | 0.810 | 0.002* | ||
| Severity of osteoarthritis | <5 points | (n=151) | 1.3 (1.9) | 1.0 (2.4) | 2.3 (4.2) | 4.6 (6.4) |
| ≥5 points | (n=244) | 4.0 (3.7) | 3.0 (4.5) | 2.8 (5.3) | 9.8 (9.7) | |
| P value | <0.001* | <0.001* | 0.275 | <0.001* | ||
| Total sample | (n=403) | 2.94 (3.41) | 2.19 (3.93) | 2.54 (4.88) | 7.67 (8.94) | |
*Statistically significant after Bonferroni correction.
†Self-rated severity score out of 10 (1=least severe and 10=most severe).
CM, complementary medicine.
Use of prescription medications by years since diagnosis of osteoarthritis and severity of osteoarthritis over the past 12 months
| Osteoarthritis characteristics | Prescription medication | ||||||||
| NSAIDs* | Opioids† | Other medications‡ | Total | ||||||
| Yes | No | Yes | No | Yes | No | Yes | No | ||
| Years since diagnosis | |||||||||
| <10 years | (n=244) | 23.2 | 34.7 | 21.4 | 33.0 | 23.3 | 32.9 | 23.8 | 36.3 |
| ≥10 years | (n=253) | 76.8 | 65.3 | 78.6 | 67.0 | 76.7 | 67.1 | 76.2 | 63.7 |
| P value | 0.048 | 0.206 | 0.280 | 0.015 | |||||
| Severity of osteoarthritis | |||||||||
| <5 points | (n=151) | 22.6 | 42.4 | 7.4 | 40.5 | 20.6 | 39.9 | 21.3 | 46.3 |
| ≥5 points | (n=244) | 77.4 | 57.6 | 92.6 | 59.5 | 79.4 | 60.1 | 78.7 | 53.7 |
| P value | <0.001¶ | <0.001¶ | 0.027 | <0.001¶ | |||||
*Non-steroidal anti-inflammatory drugs (NSAIDs) such as celebrex, mobic and meloxicam.
†Opioids such as endone, norspan and fentanyl.
‡Steroidal anti-inflammatory drugs such as cortisone, anticonvulsant medication such as lyrica, and bisphosphonates such as actonel.
§Self-rated severity score out of 10 (1=least severe and 10=most severe).
¶Statistically significant after Bonferroni correction.
Use of complementary medicine (CM) products and practices by years since diagnosis of osteoarthritis and severity of osteoarthritis over the past 12 months
| Osteoarthritis characteristics | Number of different CM products and practices used | |||||
| None | 1 | 2 | 3 or more | P value | ||
| (n=108) % | (n=88) % | (n=83) % | (n=94) % | |||
| Years since diagnosis | ||||||
| <10 years | (n=120) | 33.3 | 27.5 | 22.5 | 16.7 | 0.059 |
| ≥10 years | (n=253) | 26.9 | 21.7 | 22.1 | 29.3 | |
| Severity of osteoarthritis† | ||||||
| <5 points | (n=151) | 28.5 | 27.8 | 25.8 | 17.9 | 0.030* |
| ≥5 points | (n=244) | 28.7 | 21.3 | 19.7 | 30.3 | |
*Statistically significant after Bonferroni correction.
†Self-rated severity score out of 10 (1=least severe and 10=most severe).
Out-of-pocket expenses by years since diagnosis of osteoarthritis and severity of osteoarthritis over the past 12 months
| Osteoarthritis characteristics | Average cost | |||||
| Doctor/allied health practitioner | CM practitioner | Prescription medications | CM products and practices | Total | ||
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||
| Years since diagnosis | ||||||
| <10 years | (n=120) | $140.8 (237.5) | $123.3 (305.9) | $66.7 (174.3) | $177.1 (248.5) | $507.9 (672.4) |
| ≥10 years | (n=253) | $272.9 (415.7) | $153.6 (314.9) | $120.6 (241.7) | $239.3 (305.3) | $786.4 (898.3) |
| P value | 0.001* | 0.383 | 0.029 | 0.052 | 0.003* | |
| Severity of osteoarthritis | ||||||
| <5 points | (n=151) | $130.8 (254.7) | $118.5 (296.3) | $46.0 (125.2) | $177.1 (248.5) | $474.2 (630.6) |
| ≥5 points | (n=244) | $282.2 (408.1) | $156.6 (314.6) | $134.6 (254.5) | $239.3 (305.3) | $813.5 (905.9) |
| P value | <0.001* | 0.234 | <0.001* | 0.052 | <0.001* | |
| Total sample | (n=403) | $220.1 (362.1) | $139.2 (305.5) | $98.9 (216.8) | $214.5 (284.7) | $672.7 (823.6) |
*Statistically significant after Bonferroni correction.
†Self-rated severity score out of 10 (1=least severe and 10=most severe).
CM, complementary medicine.